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Background
The nitric oxide (NO) receptor soluble guanylyl cyclase
(sGC) is composed of two subunits of a1,2 and b1,2,
sGCa1b1 being the major heterodimer that catalyzes the
formation of second messenger cGMP. NO-cGMP signal-
ing plays a critical role in numerous processes, and
retarded signaling function by either limited NO bioavail-
ability, or decrease in expression or activity of sGC corre-
lates with several disease states including hypertension,
neurodegenerative disorders, inflammation, and cancer.
Our analysis of human databases revealed a statistically
significant reduction of sGC transcript levels in multiple
human cancer specimens including glioma and breast can-
cers. We have recently demonstrated that restoration of
sGC expression levels in glioma cell lines significantly
reduced cell proliferation, colony formation, and growth of
orthotopically implanted glioma cells in mice, suggesting a
potent anti-tumor property for the sGC. However, the
mechanism underlying the genetic silencing of sGC in
cancer is unknown.
Results and discussion
Here we report that sGCb1 is regulated epigenetically by
histone acetylation in breast and lung cancers cell lines.
Treatment with HDAC inhibitors LBH-589 (panobino-
stat), MS-275 (entinostat) and Trichostatin-A were able to
increase expression levels of sGCb1 up to 25 fold above
control in the triple negative breast cancer cell line MDA-
MB-231. However, the treatment of cells with histone
lysine demethylase inhibitor (BIX-0192); the histone lysine
demethylase inhibitor (trans-2-PCPA), and DNA methyla-
tion inhibitors (5-aza-2’-deoxycytidine and chlorogenic
acid) had no effect on sGCb1 expression. Thus, histone
acetylation plays an influential role in regulating sGCb1
expression, while other epigenetic marks such as DNA
methylation, and histone methylation do not. Over expres-
sion of histone deacetylase (HDAC) isoforms 1 and 3 sig-
nificantly reduced sGCb1 expression, and pharmacological
inhibition of histone acetyl transferase (HAT) p300/pCAF
achieved a similar result. Further analysis of the molecular
aspects of sGCb1 epigenetic regulation should offer
opportunities to target diseases, such as cancer, that are
marked by decreased sGCb1 expression.
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